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Introduction: Primary culture of cancer cells is expected to be useful 
for investigating the biology of cancer and predicting chemosensitiv-
ity for individual patients, yet has been hampered by technical diffi-
culties. We recently developed the cancer tissue–originated spheroid 
(CTOS) method for the primary culture of colorectal cancer cells. In 
the present study, we applied this system to the primary culture of 
non–small-cell lung cancer.
Methods: We used 125 surgical specimens and 18 pleural effusions for 
CTOS preparation. Partially digested tumor fragments were cultured in 
a medium for embryonic stem cells. CTOSs were subjected to sensitiv-
ity assay and signal transduction assay for the epidermal growth fac-
tor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib. We also 
investigated the effects of growth factors in culturing lung cancer CTOS.
Results: The success rate of CTOS preparation from surgical speci-
mens was 80.0%. The CTOS method was also suitable for culturing 
tumor spheroids from pleural effusions. CTOSs from lung cancer 
consisted mostly of pure cancer cells. CTOSs and CTOS-derived 
xenografts retained the characteristics of the original tumors. In vitro 
assay results showed that EGFR mutation status and expression lev-
els corresponded with erlotinib sensitivity, confirming previous clini-
cal findings. Furthermore, we found that neuregulin 1, a ligand of 
HER3, potently induced CTOS growth.
Conclusions: The CTOS method enables us to obtain primary lung 
tumor cells of high viability and purity. CTOS could be a new plat-
form for studying lung cancer biology.
Key Words: Primary culture, Non–small-cell lung cancer, EGFR 
tyrosine kinase inhibitor, Neuregulin 1, HER3.
(J Thorac Oncol. 2013;8: 131–139)
Despite constant efforts to improve diagnostics and thera-peutics, cancer remains a leading cause of death in devel-
oped countries, and pulmonary malignancies are the leading 
cause of cancer-related death worldwide. Studies have shown 
that some lung adenocarcinomas are addicted to epidermal 
growth factor receptor (EGFR) signaling, and EGFR tyro-
sine kinase inhibitors (TKIs) are effective treatment in such 
cases.1,2 However, these therapies are challenged by primary 
and acquired resistance, including additional point muta-
tions3–5 and alternative pathways that bypass the targets of 
therapeutic reagents.6–8 Other ErbB family tyrosine kinase 
receptors are also involved in non–small-cell lung carci-
noma (NSCLC);9 human epidermal growth factor receptor 3 
(HER3) is reportedly involved in the acquired resistance to 
EGFR TKI, whereas HER2 is overexpressed in 10% to 20% 
of NSCLC and carrying mutations in approximately 2%.10,11 
Bypassing EGFR signaling can be achieved through HER3 
phosphorylation by overexpressed hepatocyte growth factor 
receptor (MET),6 or by the induction of HER3 ligand as an 
autocrine loop.12 Targeting of HER2 is already in clinical use 
and that of HER3 is under clinical trial.
Much of the above described data have been obtained 
through preclinical cancer therapy research performed using 
cancer cell lines. Although cancer cell lines are originally 
established from patient tumors, they have adapted to the cul-
ture conditions, that is, serum-supplemented medium.13 Long-
term cultivation in serum-containing medium reportedly leads 
to the accumulation of genetic alterations;14,15 therefore, it 
must be considered whether cancer cell lines continue to accu-
rately represent the parental cancer cells.
Nevertheless, primary culture of cancer cells is 
expected to be useful for investigating cancer biology and 
predicting chemosensitivity for individual patients. However, 
it has been hampered by technical difficulties, including poor 
cell viability, weak growth, and contamination by host cells, 
especially fibroblasts. We recently reported a novel primary 
culture system for colorectal cancer.16 The principle of this 
method is to retain cell–cell contact during preparation. 
Tumor biopsy specimens are partially digested into fragments 
and cultured in a serum-free medium for embryonic stem 
(ES) cells; within a few hours, the irregularly shaped tumor 
fragments spontaneously form spheroids, termed cancer 
tissue–originated spheroids (CTOSs). This CTOS method 
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enables preparation and culture of multiple spheroids 
consisting of highly pure and viable colorectal cancer cells.
In the present study, we applied the CTOS method to the 
primary culture of non–small cell lung cancer (NSCLC). We 
were able to prepare and culture CTOSs from surgical speci-
mens and pleural effusion. CTOSs from NSCLC showed indi-
vidual responses to EGFR tyrosine kinase inhibitor in vitro 
and in vivo. CTOSs were also applicable in a signal transduc-
tion assay. Moreover, we identified neuregulin 1 (NRG1, also 
known as heregulin β1), a ligand for HER3, as a prominent 
growth factor for CTOS growth.
MATERIALS AND METHODS
CTOS Preparation
Surgical specimens and pleural effusion samples from 
lung cancer patients were obtained from Osaka Medical 
Center for Cancer and Cardiovascular Diseases, with the 
patients’ informed consent. Surgically resected tissues were 
minced with a scalpel into approximately 1-mm3 pieces, 
and washed with Hank’s balanced salt solution (HBSS, 
Invitrogen, Carlsbad, CA). Specimens were transferred to 
a 100-ml glass flask and digested in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 0.26 U/ml 
Liberase DH (5401089; Roche, Basel, Switzerland) and 1% 
PenStrep (Invitrogen), at 37°C for 1 to 2 hours with gentle 
stirring by a magnetic bar. Digested tissue suspensions were 
passed through 500-μm and 250-μm metal mesh filters to 
remove large masses of undigested fragments. Suspensions 
were further filtered through 100-μm and 40-μm cell strain-
ers (BD FALCON, Franklin Lakes, NJ). Fragments on the cell 
strainer and cells in the flow-through fractions were collected 
separately, and were each washed with HBSS and cultured 
in StemPro hESC medium (GIBCO, Carlsbad, CA) in a non-
treated dish (EIKEN, Tokyo, Japan). Pleural effusions were 
transferred to 50-ml tubes and centrifuged at 200 g. Pellets 
were resuspended in HBSS, filtered through 40-µm cell strain-
ers, and collected and cultured in the same manner as surgical 
specimens.
Immunohistochemistry
Immunohistochemistry was performed on formalin-
fixed, paraffin-embedded tumors and CTOSs. CTOSs were 
embedded in Matrigel growth factor reduced (GFR) (BD 
Biosciences, Bedford, MA) before fixation in formalin. 
Sections were dewaxed, rehydrated, and subjected to antigen 
retrieval by autoclave incubation in citrate buffer (pH 6.0). 
The primary antibodies used are listed in the Supplementary 
text (Supplemental Digital Content, http://links.lww.com/
JTO/A386). After secondary antibody incubation, sections 
were visualized with a fluorescence method or biotin-ampli-
fied method (Nova RED, VECTOR, Burlingame, CA).
CTOS Culture
For assessing the effects of growth factors, CTOSs were 
embedded in Matrigel GFR as described above, and cultured 
in 100 μl of basal medium containing 10 ng/ml or 100 ng/ml of 
the following growth factors: NRG1 (Peprotech, Rocky Hill, 
NJ), Long-IGF1 (Gropep, Thebarton SA, Australia), bFGF 
(Invitrogen), Activin A (R&D Systems, Minneapolis, MN), 
or EGF (Invitrogen). Basal medium consisted of DMEM/F12, 
2% BSA fraction V, 1× nonessential amino acids, 50 U/ml 
penicillin, 50 μg/ml streptomycin (all from Invitrogen), 50 μg/
ml ascorbic acid (SIGMA, St. Louis, MO), 10 μg/ml human 
transferrin (SIGMA), 0.1 mM β-mercaptoethanol (Wako, 
Osaka, Japan), and 1× trace elements A, B, C (Mediatech, 
Manassas, VA).
For assessment of the inhibitory effect of anti-HER3 
antibodies on CTOS growth, CTOSs were embedded in 
Matrigel GFR as described above, cultured in medium con-
taining 10 ng/ml NRG1 or in StemPro hESC, and treated with 
anti-HER3 antibody (cloneH3.105.5; Calbiochem, La Jolla, 
CA) at the indicated doses.
CTOS Sensitivity Assay In Vitro
For the erlotinib sensitivity assay, each CTOS was 
embedded in a gel droplet of Matrigel GFR, and cultured 
in StemPro hESC containing erlotinib (Toronto Research 
Chemicals, North York, ON, Canada) at the indicated doses. 
CTOSs were exposed to erlotinib for 7 days. CTOS viability 
was evaluated based on CTOS size at day 7, corrected for the 
CTOS size at day 0. CTOS size was measured using image 
analysis software (Image J; National Institutes of Health, 
Bethesda, MD). Half maximal (50%) inhibitory concentration 
values were calculated with GraphPad Prism 4 software, using 
the sigmoidal dose-response function.
Animal Studies
Animal studies were performed in compliance with 
the guidelines of the institutional animal study committee 
of Osaka Medical Center for Cancer and Cardiovascular 
Diseases. Primary xenograft tumors were generated by inoc-
ulating small pieces of patient tumors into non-obese dia-
betic/severe combined immunodeficient (NOD/Scid) mice. 
One hundred CTOSs were suspended in 50 μl of Matrigel 
GFR, and transplanted subcutaneously into the flanks of 
NOD/scid mice. CTOSs prepared from mouse xenografts 
are designated with the postfix “m” in the figures. Treatment 
was started when the tumor volume reached approximately 
65 mm3. Erlotinib (Tarceva, CHUGAI Pharmaceutical, 
Tokyo, Japan) was suspended in 0.5% methyl cellulose, and 
administered at a dose of 100 mg/kg orally once a day, ×5, 
for 2 weeks.
Western Blot
CTOSs were cultured overnight in growth factor-free 
DMEM-F12, and pulsed with StemPro hESC supplement 
or 10 ng/ml of the indicated growth factors for 15 minutes. 
CTOSs were lysed with cell lysis buffer (10 mM Tris (pH 
7.4), 0.15 M NaCl, 1% NP40, 0.25% sodium deoxycholate, 
0.05 M NaF, 2 mM EDTA, 0.1% SDS, 2 mM NaVO
4
, 10 μg/
ml aprotinin, 10 μg/ml leupeptin, and 1 mM PMSF). Western 
blot was performed as previously described.17 For signal 
transduction assays under erlotinib treatment, CTOSs were 
cultured overnight under growth-factor–starved conditions, 
incubated for 1 hour with erlotinib, and pulsed with 10 ng/
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ml epidermal growth factor (EGF) for 15 minutes. Primary 
antibodies used are listed in the Supplemental text.
Statistical Analysis
Data are expressed as mean, SD. Statistical analysis was 
performed using Student’s t test. Differences were considered 
significant at p values less than 0.05.
RESULTS
Preparation and Characterization of 
CTOSs from Lung Cancer Patients
To apply the CTOS technology16 to NSCLC, surgically 
resected tumor tissues were mechanically minced and enzy-
matically digested. Samples were then filtered through cell 
strainers and divided into two fractions: the organoid fraction 
(tissue fragments on the cell strainer) and the flow-through 
fraction. The irregular-shaped fragments in the organoid 
fraction formed spheroids within a few hours in a serum-free 
medium for ES cell culture (Fig. 1A, Supplementary Fig. 1A, 
http://links.lww.com/JTO/A355). The flow-through fraction 
mostly consisted of single cells, small-cell aggregates, and 
debris; we occasionally found small CTOS-like structures in 
the flow-through fraction, probably derived from cell aggre-
gates (Supplementary Fig. 1B, http://links.lww.com/JTO/
A355). CTOSs were also prepared from pleural effusions, 
without any dissociation process (Fig. 1B). When CTOSs 
were dissociated into single cells by trypsin treatment, the 
dead cells increased over time (Supplementary Fig. 1C, 
http://links.lww.com/JTO/A355). Thus, retaining cell–cell 
contact was crucial for preparation and maintenance of via-
ble lung cancer cells, as previously observed in CTOSs of 
colorectal cancer.16
Flow cytometric analysis revealed that CTOSs from 
adenocarcinoma mostly consisted of epithelial cell adhesion 
molecule (EpCAM)–positive epithelial cells. CD45-positive 
hematopoietic cells were barely detectable in CTOSs (Fig. 
1C). In contrast, cells in the flow-through fraction consisted 
of various types of cells, including EpCAM-negative non-
epithelial cells and CD45-positive cells (Fig. 1C). Next, we 
assessed the purity of CTOSs by immunohistochemistry. The 
original patient tumors consisted of various type of cells, 
including epithelial cells (E-cadherin positive), myofibro-
blasts (α-smooth muscle actin [α-SMA] positive), and mac-
rophages (CD68 positive). In contrast, the cells in CTOSs 
were almost exclusively E-cadherin positive (Fig. 1D). Thus, 
highly pure epithelial cells could be prepared from bulk 
tumor tissues by the CTOS method.
CTOSs were successfully prepared from 100 of 125 
NSCLC samples (80.0%) from surgically resected tumors, 
and in eight of 18 pleural effusion samples (44.4%), including 
all histologic subtypes (Table 1, Supplementary Table 1, 
Supplemental Digital Content 2, http://links.lww.com/JTO/
A356). In most of the failed cases, tumor fragments were not 
observed in the effusion. CTOSs were also prepared from 
small-cell lung cancer (Supplementary Table 1, Supplemental 
Digital Content 2, http://links.lww.com/JTO/A356). CTOSs 
were successfully prepared from all (5 of 5) primary xenograft 
FIGURE 1.  Preparation and characterization of CTOSs from 
patients’ lung tumors. A, H&E staining of original tumor and 
phase contrast images of organoid fraction at the indicated 
times after OMLC-58 preparation. Low- (upper panels) and 
high-magnification (lower panels) images are shown. Scale 
bar: 200 μm. B, Phase contrast images of CTOSs from three 
independent pleural effusion samples. Scale bar: 200 μm. C, 
Flow cytometric analysis of the indicated cell-surface antigens 
by specific antibodies (solid line) or isotype controls (gray 
filled). D, OMLC-40 subjected to H&E staining and immu-
nohistochemistry of E-cadherin (green), α-SMA (red), CD68 
(red), and Hoechst33342 (blue). Scale bar: 75 μm. H&E, 
hematoxylin and eosin.
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tumors, which were generated by inoculating small pieces of 
patient tumors into NOD/scid mice.
CTOS Preserved the Original 
Tumor Characteristics
To examine the tumorigenic capacity of CTOS, 100 
CTOSs (approximately 1 × 104 cells) were transplanted into 
the flanks of NOD/scid mice. When primary CTOSs pre-
pared from patient tumors were subcutaneously injected 
into immunodeficient mice, the CTOSs from six of 18 
cases (33.3%) formed xenograft tumors (Supplementary 
Table 1, Supplemental Digital Content 2, http://links.lww.
com/JTO/A356). However, CTOSs from primary xenograft 
tumors formed xenograft tumors in four of five cases (80%). 
Histologic analysis revealed that CTOSs and mouse xeno-
graft tumors exhibited characteristics of the original patient 
tumors, at least of some parts in mixed subtype tumors (Fig. 
2A). Xenografts or CTOSs also preserved the immunohis-
tochemical characteristics of the original tumors, including 
staining patterns of EGFR, CK7, TP53, and neural cell adhe-
sion marker (Fig. 2B, Supplementary Fig. 2, Supplemental 
Digital Content 3, http://links.lww.com/JTO/A357). The ratio 
of CD133-positive cells, a reported marker of cancer stem 
cells (CSCs) in lung cancer,18 was not enriched in CTOSs 
(Supplementary Fig. 3, Supplemental Digital Content 4, 
http://links.lww.com/JTO/A358).
Response of Lung CTOSs to EGFR TKI
We successfully grew lung CTOSs in vitro in StemPro 
medium, embedded in Matrigel GFR (Supplementary Fig. 4A, 
Supplemental Digital Content 5, http://links.lww.com/JTO/
A358). Under these culture conditions, 67.2% of CTOSs 
grew to more than 1.2 times their original size after 7 days 
(Supplementary Fig. 4B, Supplemental Digital Content 5, 
http://links.lww.com/JTO/A359). CTOSs from adenocarci-
nomas tended to grow better compared with those from squa-
mous cell carcinomas.
FIGURE 2.  CTOS-derived xenotumors preserved the original characteristics of parental tumors. A, H&E staining of the 
indicated cases. B, Immunohistochemistry of EGFR from the indicated cases. Original tumor (left column), CTOS (middle col-
umn), and xenograft tumor (right column). Adeno, adenocarcinoma; Squamous, squamous cell carcinoma; LCNEC, large-cell 
neuroendocrine carcinoma. Scale bar: 100 μm.
TABLE 1.  Success Rate of CTOS Formation from Lung 
Cancer Specimen
Sample  
Number
CTOS  
Formation
Success  
Rate (%)
Surgical sample Ad 82 64 78.0
AdSq 6 6 100
Sq 31 25 80.6
Large 4 4 100
Pleomorphic 2 1 50.0
Total 125 100 80.0
Pleural effusion Ad 15 7 47
AdSq 1 1 100
Sq 2 0 0
Total 18 8 44.4
(8)a (8)a (100)a
CTOS, cancer tissue–originated spheroid; Ad, adenocarcinoma; Sq, squamous 
cell carcinoma; AdSq, adenosquamouse cell carcinoma,; Large, large-cell carcinoma, 
Pleomorphic, pleomorphic carcinoma.
aExcluding samples without any tumor fragments after filtration of the pleural 
effusion
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The EGFR TKIs gefitinib and erlotinib are known 
to be effective against lung cancer harboring active EGFR 
mutations1,19 or EGFR gene amplification.20,21 We examined 
whether the response of CTOSs to EGFR TKI was con-
sistent with these clinical findings, and found that erlotinib 
sensitivity varied among individual patients (Fig. 3A). Three 
EGFR active mutant cases and one gene amplification case 
were among the top five most sensitive cases (Supplementary 
Fig. 5A and B, Supplemental Digital Content 6, http://links.
lww.com/JTO/A360). One advantage of analyzing CTOSs is 
the ability to assess the status of intracellular signaling and 
the change of status after drug treatment in individual patient 
samples. We subjected the CTOSs to immunoblot analysis to 
investigate the effect of erlotinib on intracellular signaling. 
EGFR mutants (OMLC-44, OMLC-53, and OMLC-65) and 
the EGFR overexpresser (OMLC-145) showed high levels 
of phosphorylation of EGFR and AKT, even under growth-
factor–starved conditions, indicating constitutive activation of 
EGFR signaling (Fig. 3B). In these cases, the phosphorylation 
of EGFR, AKT, and extracellular signal-regulated kinase, was 
FIGURE 3.  Effect of erlotinib on CTOS growth and signal transduction. A, In vitro dose–response curve of erlotinib sensitivity 
with 10 clinical cases. Origins of the cases are indicated in ascending order of IC50. B, Western blot of EGFR signaling pathway 
from 10 clinical cases, in ascending order of IC50. CTOSs were cultured under growth-factor–starved conditions and pulsed for 
15 minutes with 10 ng/ml EGF in the presence or absence of 1 μM erlotinib. C, Effects of erlotinib on the growth of xenograft 
tumors derived from OMLC-145 (EGFR overexpresser), OMLC-10 (EGFR-nonexpresser), OMLC-149 (EGFR wt), and OMLC-
40 (EGFR wt). The CTOSs were transplanted in NOD/SCID mice (n = 5). Erlotinib was administered orally once a day ×5 for 2 
weeks, indicated as black bars. Tumor volume at each time point (V) was corrected by that on day 1 (V0). Open circles, vehicle-
treated controls; closed circles, erlotinib-treated groups. IC50, inhibitory concentration. *p < 0.05
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diminished after erlotinib treatment, even in the presence of 
the EGFR ligand EGF.
One case of CTOS (OMLC-149), in which we could 
detect neither known EGFR mutations nor EGFR gene ampli-
fication, showed high sensitivity to erlotinib and gefitinib, 
whereas other CTOSs with wild-type EGFR were resistant 
to erlotinib (Fig. 3A, Supplementary Fig. 5C and D). The 
phosphorylation of EGFR under starved conditions was not 
high; however, in contrast with other EGFR wild-type cases, 
the phosphorylation of both AKT and ERK was substantially 
high, which was suppressed by erlotinib treatment.
Next, we assessed whether the results of the CTOS sensi-
tivity assay or the signal analysis in vitro reflected the sensitivity 
to erlotinib in vivo using the following four CTOSs: OMLC-
145 (erlotinib sensitive, EGFR gene amplification), OMLC-10 
(erlotinib resistant, EGFR not expressed), OMLC-149 (erlo-
tinib sensitive, EGFR wild-type), and OMLC-40 (erlotinib 
resistant, EGFR wild-type). We transplanted these CTOSs into 
the flanks of NOD/SCID mice. Consistent with the results of 
the in vitro experiments, growth of the tumors derived from 
erlotinib-sensitive CTOSs was suppressed by erlotinib treat-
ment, whereas no effect was observed in the tumors derived 
from erlotinib-resistant CTOSs (Fig. 3C). Thus, the results of 
the in vitro CTOS sensitivity assay and signal transduction 
assay with an EGFR inhibitor were in parallel with the thera-
peutic efficacy in vivo in the four examined cases.
Neuregulin 1 Stimulated CTOS Growth In Vitro
To determine which growth factors contributed to the 
CTOS growth in culture, we performed an assay in which 
the growth factors NRG1/heregulinβ1, insulin-like growth 
factor (IGF), basic fibroblast growth factor (bFGF), activin 
A, and epidermal growth factor (EGF), in StemPro hESC22 
were added one at a time to the basal medium. In 10 of 13 
cases (71.4%) tested, the HER3 ligand NRG1 showed the 
most potent effect on CTOS growth at the dose compatible 
to that of StemPro hESC (Figure 4, Supplementary Table 
1, Supplemental Digital Content 2, http://links.lww.com/
JTO/A356). In contrast, EGF showed only a minimal effect 
on CTOS growth, and occasionally showed a toxic effect 
(Fig. 4; OMLC-145). Among the tested cases, two CTOSs 
from squamous cell carcinoma did not respond to NRG1 
(Supplementary Table 1, Supplemental Digital Content 2, 
http://links.lww.com/JTO/A356).
Analysis of intracellular signaling revealed that NRG1 
was the most potent inducer of AKT phosphorylation (Fig. 5A). 
Next, we analyzed the localization of HER3 phosphorylation 
by NRG1 in CTOSs by immunohistochemistry (Fig. 5B). 
Phosphorylation of HER3 and AKT was detected after NRG1 
stimulation. As demonstrated by ZO-1/E-cadherin and EGFR 
staining, the CTOSs from OMLC-53 had polarity, in which 
the apical side was outside of CTOSs (Fig. 5B). HER3 phos-
phorylation was detected at the basolateral membrane of the 
cells in the CTOS. However, CTOSs from OMLC-128 did not 
show clear polarity.
We then challenged the CTOSs cultured in NRG1-
containing medium or StemPro hESC with a neutralizing 
antibody against HER3.23 The growth (Fig. 5C) and the phos-
phorylation of HER3 and AKT (Fig. 5D) were partially sup-
pressed by the antibody. Taken together, our findings show 
FIGURE 4.  NRG1stimulated CTOS growth in vitro. Growth ratio of CTOSs from six cases at day 7 relative to day 0. The CTOSs 
were embedded in Matrigel growth factor reduced and cultured in StemPro hESC or defined conditions containing NRG1, 
Long-IGF (IGF), bFGF, Activin A (Activin), or EGF at 10 ng/mlL or 100 ng/ml. *p < 0.05.
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that NGR1/HER3 signaling played a role in the culture of lung 
CTOSs.
DISCUSSION
Primary culture of lung cancer cells has been attempted 
for decades, using two basic approaches: histoculture and dis-
sociation-based culture. In histoculture, tumors are cultured 
directly24,25 or on gel matrices after being minced into small 
pieces.26–28 In dissociation-based culture, tumors are enzymat-
ically dissociated into single cells or cell aggregates of several 
cells; then the cells or cell aggregates are cultured on the dish29 
or in gel matrices.30,31 In these methods, the cultured cells are 
mixtures of tumor cells and host cells in varying degrees. In 
contrast, CTOS technology enables us to culture mostly puri-
fied lung cancer cells as spheroids in a medium with defined 
growth factors, and allows us to obtain reproducible results; 
these features are essential for bioassays, such as treatment 
sensitivity assays and pathway-activation assays.
The success rate of preparing CTOSs from lung cancer 
was 80.0%, which is relatively low compared with the high 
success rate (98.7%) achieved with colorectal cancer.16 This 
difference may be partly because of the relatively poor con-
tent of cancer cells in the lung cancer samples. In addition, 
as lung cancer tissues contain more fibrous component than 
colorectal cancer tissues do, optimizing the protocol of tissue 
dissociation might improve the CTOS preparation from tiny 
biopsy samples of lung cancer. The success rate of tumor for-
mation with lung cancer CTOSs in NOD-scid mice was also 
relatively low, 33.3%, compared with the results with colorec-
tal cancer.16 Compared with colorectal cancer, lung cancer cell 
growth might be more dependent on the cancer-associated 
microenvironment, which might not be replicated in mouse 
subcutaneous tissue.
CSC theory has been recently proposed and widely 
investigated; this theory states that only a minor population of 
cancer cells has the capacity of self-renewal and multipotency 
of differentiation; therefore, cancers form with a hierarchy 
dominated by the CSCs.18,32 CTOSs share some characteristics 
of CSCs, including sphere-forming capacity in suspension 
culture with serum-free medium, and tumorigenic capac-
ity in immunodeficient mice. However, CTOSs and CSC-
derived spheroids are different in several aspects. First, lung 
CSCs are reportedly CD133-positive cells, which are rare in 
tumors and enriched in CSC-derived spheroids,18 whereas 
the level of CD133-positive cells was not enriched in CTOSs 
(Supplementary Fig. 3, Supplemental Digital Content 4, http://
links.lww.com/JTO/A358). Second, the expression levels of 
FIGURE 5.  Effect of NRG1 on path-
way activation in CTOSs. A, Western 
blot for ErbB family signaling path-
way of OMLC-128 and OMLC-53. 
CTOSs were cultured under growth-
factor–starved conditions and stimu-
lated by 10 ng/ml of each indicated 
growth factor for 15 minutes. B, 
Immunohistochemistry of phospho-
HER3 and phospho-AKT after NRG1 
stimulation. OMLC-128 or OMLC-53 
CTOSs were cultured under starva-
tion conditions and stimulated by 
10 ng/ml NRG1 for 6 hours (pHER3) 
or 1 hour (pAKT). EGFR, ZO1, and 
E-cadherin staining indicate the 
polarity of the CTOSs. C, Inhibitory 
effect of anti-HER3 antibody on 
growth of OMLC-128 CTOSs. CTOSs 
were embedded in Matrigel growth 
factor reduced, cultured in basal 
medium containing 10 ng/ml NRG1 
or StemPro hESC, and treated with 
the indicated doses of anti-HER3 
antibody. *p < 0.05. D, Effect of anti-
HER3 antibody on signal transduction 
of OMLC-128. CTOSs were cultured 
in StemPro containing the indicated 
dose of anti-HER3 antibody for 24 
hours. StemPro hESC; IGF; long-IGF1, 
Activin; Activin A.
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differentiation markers, including cytokeratin and neural cell 
adhesion marker, are reportedly low in CD133-positive cells,18 
whereas the expression levels of these markers in CTOSs were 
similar to those in the original tumors (Supplementary Fig. 2, 
Supplemental Digital Content 3, http://links.lww.com/JTO/
A357). Thus, the cells comprising the CTOS represented the 
major population of cancer cells within the patient’s tumor, 
and are not likely derived from a minority cell population in 
the tumor, although our experiments do not exclude the exis-
tence of CSCs in CTOSs.
We showed that the CTOS method can be used to eval-
uate EGFR signaling and the response to an EGFR TKI in 
primary cultured lung cancer cells from individual patients. 
Tumors harboring EGFR-activating mutations and gene 
amplification are known to be clinically sensitive to EGFR 
TKIs,1–3,20,21 and correspondingly, these cases were sensitive 
to erlotinib in the CTOS assay in vitro (Fig. 3A). In terms 
of intracellular signaling, the levels of AKT phosphorylation 
are reportedly high in EGFR TKI–sensitive patients or cell 
lines.21,33 Indeed, in the erlotinib-sensitive CTOSs, the rates 
of phosphorylation of EGFR and AKT were high even under 
growth-factor–starved conditions, and were completely sup-
pressed by erlotinib treatment. We also found one CTOS with 
wild-type EGFR and no gene amplification to be sensitive to 
erlotinib in vitro and in vivo. Thus, CTOS might provide an 
alternative method for selecting patients for molecular-tar-
geted drugs, in addition to the snapshot of information given 
by assessing biopsy samples. Further studies are required to 
test the relationship between the sensitivity assay with CTOSs 
and the patients’ clinical response to specific treatments and 
determine whether the CTOS method is useful for personal-
ized medicine.
We found here that NRG1-HER3 signaling is impor-
tant for CTOS culture from NSCLC. NRG1 showed the most 
potent effect on CTOS growth in 71.4% cases at the tested 
doses, yet other growth factors also promoted CTOS growth 
to some extent (Fig. 4). In some cases, the growth-promot-
ing effect of NRG1 was saturated at 10 ng/ml. This might 
be because of the internalization and degradation of HER3 
after ligand binding. HER3 is a member of ErbB family of 
transmembrane tyrosine kinase receptors. HER3 lacks tyro-
sine kinase activity, and transduces downstream signals by 
forming heterodimers with other tyrosine kinase receptors.9 
As HER3 has six docking sites for phosphatatidylinositol-3 
kinase (PIK3) p85, it can potently activate the PI3K-AKT 
pathway.34 Among the growth factors examined in this 
study, NRG1 most strongly induced AKT phosphorylation 
in CTOSs (Fig. 5A). Despite the growth-promoting effect of 
NRG1 on the CTOSs, we only observed a marginal inhibi-
tory effect of the anti-HER3 antibody (Fig 5D). This might 
be because of the antibody’s ability to block signaling; it is 
also possible that the tight junctions in CTOSs (illustrated by 
ZO-1 staining in Fig. 5B) stopped the antibody from penetrat-
ing sufficiently.
The NRG1-HER3 pathway plays important roles in 
the maintenance of normal airway epithelium.35 HER3 and 
its ligands are both constitutively expressed in normal lung 
alveolar cells. NRG1 is secreted to the apical side, whereas 
HER3 is expressed in the basolateral side; thus, HER3 has 
no access to the ligands. Upon injury to the alveolar epithe-
lium, NRG1 binds to HER3 and the signal contributes to 
wound healing. Lung cancer might use the wound healing 
system of normal lung epithelium. In our experiments with 
CTOSs, NRG1 was the most potent inducer of proliferation 
and AKT phosphorylation (Fig. 5A). The phosphorylation of 
HER3 after NRG1 treatment was observed on the basolateral 
membrane (Fig. 5B). In StemPro hESC, CTOSs from squa-
mous cell carcinomas showed relatively poor growth com-
pared with CTOSs from adenocarcinomas (Supplementary 
Fig. 4B, Supplemental Digital Content 5, http://links.lww.
com/JTO/A359). In addition, two CTOSs from squamous 
cell carcinomas did not depend on any of the growth factors 
tested (Supplementary Table 1, Supplemental Digital Content 
2, http://links.lww.com/JTO/A356). These results suggest that 
CTOSs from squamous cell carcinomas require growth fac-
tors other than those tested in the present study. It was recently 
reported that NRG1-HER3 signaling promotes mammosphere 
formation from breast cancer–derived single cells.36 NRG1 
might exert an effect on the three-dimensional culture of can-
cer cells; although in CTOSs, NRG1 was not necessary for 
their formation.
It is reported that activation of PI3K-AKT by EGFR 
requires HER3, using gefitinib-sensitive cell lines.37 NRG1 is 
also reported to promote tumor growth in two of eight lung 
adenocarcinoma cell lines (25%), and both of the responders 
were EGFR mutants.38 However, in the present study, some 
of the EGFR wild-type CTOSs also responded to NRG1 
(Supplementary Table 1, Supplemental Digital Content 2, 
http://links.lww.com/JTO/A356), probably via phosphory-
lation of HER3 by HER2. These results suggested that the 
role of HER3 signaling might not be restricted to the EGFR 
mutants. Further studies are required to assess whether NRG1 
alone can be substituted for StemPro hESC and allow not 
only growth, but also maintenance of original characters, and 
tumorigenicity of CTOSs.
In conclusion, the present findings show that the novel 
CTOS method can be successfully used to obtain primary lung 
tumor cells of high viability and purity. Thus, it is possible 
that CTOSs could be a new platform for studying lung cancer 
biology, and for examining an individual patient’s response to 
clinical treatment.
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